Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival.
作者信息
Merino Margret, Kasamon Yvette, Theoret Marc, Pazdur Richard, Kluetz Paul, Gormley Nicole
机构信息
Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.
Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD.
出版信息
J Clin Oncol. 2023 May 20;41(15):2706-2712. doi: 10.1200/JCO.23.00225. Epub 2023 Mar 17.
Abstract
摘要
相似文献
1
Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival.不可调和的差异：缓解率、无进展生存期和总生存期之间的脱节
J Clin Oncol. 2023 May 20;41(15):2706-2712. doi: 10.1200/JCO.23.00225. Epub 2023 Mar 17.
2
[Divorces, 1985].[1985年离婚情况]
Wirtsch Stat. 1986 Dec(12):968-73.
3
[Family, stability, and divorce].[家庭、稳定性与离婚]
Viitorul Soc. 1986 Sep-Oct:467-76.
4
5
[Regional differences concerning divorce in Czechoslovakia].[捷克斯洛伐克离婚情况的地区差异]
Demografie. 1987;29(4):310-7.
6
[Socio-demographic aspects of the family around the world].[世界各地家庭的社会人口学特征]
Anthropotes. 1996 Jun;12(1):119-32.
7
[Trends in the divorce rate in Bulgaria].[保加利亚的离婚率趋势]
Naselenie. 1986;4(4):42-51.
8
[Divorces, 1989].[离婚，1989年]
Wirtsch Stat. 1990 Dec(12):837-40.
9
A preliminary analysis of divorce in China.中国离婚情况的初步分析。
Chin J Popul Sci. 1994;6(2):189-99.
10
Demographic determinants of delayed divorce.延迟离婚的人口统计学决定因素。
J Divorce. 1989;13(1):97-112. doi: 10.1300/J279v13n01_06.
引用本文的文献
1
Sintilimab Plus Axitinib for Advanced Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial.信迪利单抗联合阿昔替尼治疗晚期富马酸水合酶缺陷型肾细胞癌：一项2期非随机临床试验。
JAMA Oncol. 2025 Aug 14. doi: 10.1001/jamaoncol.2025.2497.
2
Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study.获批加速批准的抗癌药物适应症撤销的预测因素：一项回顾性队列研究。
EClinicalMedicine. 2025 May 31;84:103088. doi: 10.1016/j.eclinm.2025.103088. eCollection 2025 Jun.
3
The Food and Drug Administration pooled analysis of overall survival according to depth of response in frontline advanced immune-oncology renal cell carcinoma trials.美国食品药品监督管理局对一线晚期免疫肿瘤学肾细胞癌试验中根据缓解深度进行的总生存期汇总分析。
JNCI Cancer Spectr. 2025 Jul 1;9(4). doi: 10.1093/jncics/pkaf069.
4
Pathologic Complete Response and Survival in Rectal Cancer: A Systematic Review and Meta-Analysis.直肠癌的病理完全缓解与生存：一项系统评价和荟萃分析
JAMA Netw Open. 2025 Jul 1;8(7):e2521197. doi: 10.1001/jamanetworkopen.2025.21197.
5
Geneva Homologous Recombination Deficiency Test Is Predictive of Survival Benefit From Olaparib and Bevacizumab Maintenance in Ovarian Cancer.日内瓦同源重组缺陷检测可预测奥拉帕利和贝伐单抗维持治疗对卵巢癌患者生存的获益情况。
JCO Precis Oncol. 2025 Jul;9:e2400825. doi: 10.1200/PO-24-00825. Epub 2025 Jul 2.
6
Anti-Programmed Cell Death-1 Versus Anti-Programmed Death-Ligand 1 (PD-L1) in PD-L1-Negative Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.程序性细胞死亡蛋白1拮抗剂与程序性死亡配体1（PD-L1）拮抗剂在PD-L1阴性晚期非小细胞肺癌中的应用：一项系统评价与Meta分析
World J Oncol. 2025 Jun;16(3):299-310. doi: 10.14740/wjon2520. Epub 2025 Apr 22.
7
Monitoring overall survival in pivotal trials in indolent cancers.监测惰性癌症关键试验中的总生存期。
Stat Biopharm Res. 2025;17(2):161-172. doi: 10.1080/19466315.2024.2365648. Epub 2024 Sep 3.
8
Impact of neutrophil-to-lymphocyte ratio on survival outcomes among cirrhotic and non-cirrhotic patients with advanced hepatocellular carcinoma under atezolizumab-bevacizumab combination therapy.在接受阿替利珠单抗-贝伐单抗联合治疗的晚期肝细胞癌肝硬化和非肝硬化患者中，中性粒细胞与淋巴细胞比值对生存结果的影响。
Ann Gastroenterol. 2025 May-Jun;38(3):319-327. doi: 10.20524/aog.2025.0963. Epub 2025 Apr 22.
9
Emerging therapeutics targeting tumor-associated macrophages for the treatment of solid organ cancers.靶向肿瘤相关巨噬细胞治疗实体器官癌症的新兴疗法。
Expert Opin Emerg Drugs. 2025 Jun;30(2):109-147. doi: 10.1080/14728214.2025.2504376. Epub 2025 May 25.
10
Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors.抗白细胞介素-1受体辅助蛋白单克隆抗体纳杜诺单抗与帕博利珠单抗联合用于实体瘤患者的安全性、耐受性及初步疗效
Invest New Drugs. 2025 May 1. doi: 10.1007/s10637-025-01538-3.
本文引用的文献
1
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.伊布替尼联合苯达莫司汀和利妥昔单抗治疗未经治疗的套细胞淋巴瘤。
N Engl J Med. 2022 Jun 30;386(26):2482-2494. doi: 10.1056/NEJMoa2201817. Epub 2022 Jun 3.
2
The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint.血液系统恶性肿瘤中PI3K抑制剂的传奇故事：生存是最终的安全性终点。
Lancet Oncol. 2022 May;23(5):563-566. doi: 10.1016/S1470-2045(22)00200-5. Epub 2022 Apr 14.
3
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.鲁卡帕利与标准护理化疗用于复发性卵巢癌且携带有害 BRCA1 或 BRCA2 突变患者的对比（ARIEL4）：一项国际性、开放性标签、随机、3 期临床试验。
Lancet Oncol. 2022 Apr;23(4):465-478. doi: 10.1016/S1470-2045(22)00122-X. Epub 2022 Mar 14.
4
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.来那度胺耐药的多发性骨髓瘤患者使用美法仑或泊马度胺联合地塞米松治疗（OCEAN）：一项随机、头对头、开放标签、3 期研究。
Lancet Haematol. 2022 Feb;9(2):e98-e110. doi: 10.1016/S2352-3026(21)00381-1. Epub 2022 Jan 12.
5
The Drug-Dosing Conundrum in Oncology - When Less Is More.肿瘤学中的给药难题——少即是多。
N Engl J Med. 2021 Oct 14;385(16):1445-1447. doi: 10.1056/NEJMp2109826. Epub 2021 Oct 9.
6
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.特普替尼治疗转移性葡萄膜黑色素瘤的总生存获益。
N Engl J Med. 2021 Sep 23;385(13):1196-1206. doi: 10.1056/NEJMoa2103485.
7
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.Copanlisib 联合利妥昔单抗与安慰剂联合利妥昔单抗治疗复发惰性非霍奇金淋巴瘤（CHRONOS-3）：一项双盲、随机、安慰剂对照、3 期临床试验。
Lancet Oncol. 2021 May;22(5):678-689. doi: 10.1016/S1470-2045(21)00145-5. Epub 2021 Apr 10.
8
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.仑伐替尼联合帕博利珠单抗或依维莫司治疗晚期肾细胞癌。
N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13.
9
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.维奈托克或安慰剂联合硼替佐米和地塞米松治疗复发或难治性多发性骨髓瘤患者（BELLINI）：一项随机、双盲、多中心、3 期临床试验。
Lancet Oncol. 2020 Dec;21(12):1630-1642. doi: 10.1016/S1470-2045(20)30525-8. Epub 2020 Oct 29.
10
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.奥拉帕利对比铂类敏感复发卵巢癌且携带胚系 BRCA1/2 突变患者的非铂类化疗（SOLO3）：一项随机 III 期临床试验。
J Clin Oncol. 2020 Apr 10;38(11):1164-1174. doi: 10.1200/JCO.19.02745. Epub 2020 Feb 19.
Zotero 插件